To view a copy of this licence, visit About this article Cite this article Chen, H., Liu, S., Gao, S
The study, which was published in the JCO Oncology Practice journal, looked at University of Pennsylvania Health System records from more than 111,000 women ages 45 to 80 over the last several years who were overweight or obese, to see who went on to develop breast cancer
[ 3 ] Additionally, a study of 2,405 patients found an average weight loss of 2.2% after 72 weeks on GLP-1 medications
Less commonly associated side effects include hypoglycemia, acute pancreatitis, increased risk of gallbladder and biliary diseases, renal insufficiency or acute renal failure, retinopathy, and thrombocytopenia (low platelet count)
What to Expect When Beginning GLP-1 Peptide Therapy Treatment begins gradually
It is up to each insurer and its chief medical officer to decide if these medications will be covered